ClinicalTrials.gg
RecruitingNCT04830137Updated Mar 20, 2026

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

A Phase 1 interventional study of NX-2127 in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) and Waldenstrom Macroglobulinemia (WM), sponsored by Nurix Therapeutics, Inc.. Recruiting at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Nurix Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
248
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 136 open to participants now, 251 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.

Planned enrollment
102nd of 1,298
248 · median 36
Started
2021
with 39 others
Phase 1
485 of 1,501
26 open now
Primary completion
2026-05
later than 50 of 247 live
Registered
1,325th of 1,501
by date

Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 102nd largest by planned enrollment of the 1,298 interventional ones that give a count, is one of 40 that started in 2021, is one of 485 in phase 1, reaches primary completion later than 50 of the 247 other live ones, and was the 1,325th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

136 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:

131 more — sign in →

All 136 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

Read the detailed description

Phase 1a (Dose Escalation) will evaluate the safety and tolerability of NX-2127 in adult patients with relapsed/refractory (R/R) B-cell malignancies, who have required and received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and for which no other therapies are known to provide clinical benefit.

Phase 1b (Dose Optimization) will use a 2-stage design to further investigate the safety, tolerability, and preliminary efficacy of NX-2127 in R/R B-cell malignancies based on the dosage(s) selected in Phase 1a.

Stage 1 will enroll approximately 10 participants per group based on B-cell lymphoma/leukemia indication at a specific dose selected from the first part of the study. The Sponsor may decide to open Stage 2 for any given group after review of safety and anti-tumor activity data from Stage 1.

In Stage 2, an additional 10 participants will be enrolled at the dose from Stage 1 as well as 20 additional participants at a second alternative dose. Participants will be randomly assigned to one of the 2 dose levels in Stage 2.

03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Waldenstrom Macroglobulinemia (WM)
  • Mantle Cell Lymphoma (MCL)
  • Marginal Zone Lymphoma (MZL)
  • Follicular Lymphoma (FL)
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Primary Central Nervous System Lymphoma (PCNSL)

Keywords

  • BTK Degrader
  • BTK Inhibitor
  • B-cell Malignancy
  • Lymphoma
  • IMiD
  • Lenalidomide
  • Pomalidomide
  • Bruton's Tyrosine Kinase
  • NX-2127
  • Targeted Protein Degradation
  • Chimeric Targeting Molecule (CTM)
  • C481
  • C481S
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must be ≥ 18 years of age
  • Patients must have per disease-specific response criteria
  • Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, Lugano Classification of Lymphoma response criteria, or International PCNSL Collaborative Group response criteria)
  • Patients with transformed lymphoma are eligible for the study with the exception of those detailed in Exclusion Criteria #1: Prolymphocytic leukemia, MCL with blastoid histology, MCL with pleomorphic morphology, or MCL with known TP53 mutation
  • (ECOG) performance status of 0 or 1 (non-PCNSL indications) or 0 - 2 (PCNSL patients)
  • Adequate organ and bone marrow function
  • Patients of must use adequate measures to avoid pregnancy for the duration of the study as defined in the protocol

Inclusion Criteria for Patients in Phase 1a:

  • Have confirmed R/R CLL, SLL, WM, MCL, and MZL, FL, DLBCL, or PCNSL
  • Received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and have no other therapies known to provide clinical benefit
  • Must require systemic therapy

Inclusion Criteria for Patients in Phase 1b:

  • Must have one of the following histologically documented R/R B-cell :

    • CLL/SLL whose disease has failed treatment with a BTKi;
    • MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen
    • FL or MZL whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTKi
    • PCNSL whose disease failed at least 1
    • DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen, or another/ palliative regimen (either progressed post stem cell transplant or transplant-ineligible)

Exclusion Criteria:

  • Active, uncontrolled hemolytic anemia or autoimmune thrombocytopenia
  • History of known/suspected other autoimmune disease (exception(s): patients with alopecia, vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed.)
  • Unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug
  • Bleeding diathesis, or other known risk for acute blood loss
  • Patients requiring ongoing treatment with warfarin or an equivalent vitamin K antagonist and within 7 days prior to the first dose of study drug
  • Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)
  • Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy, peripheral neuropathy or hematologic parameters meeting inclusion criteria).
  • Active known second malignancy. Exception: patients with non-, non-melanoma skin cancer are eligible
  • Patient has had major surgery (e.g. requiring general anesthesia) within 4 weeks before the planned first dose of study drug
  • Infection with (HIV)-1 or HIV-2. Exception: patients with well-controlled HIV (e.g., > 350/mm3 and undetectable viral load) are eligible.
  • Current active liver disease from any cause
  • Active viral reactivation (e.g., CMV or EBV)
  • Use of systemic exceeding 20 mg/day prednisone (or equivalent) for non-PCNSL indications within 15 days prior to the planned start of study drug. PCNSL patients may not exceed corticosteroid doses of 40 mg/day prednisone (or equivalent) and should be on a stable or decreasing dose for 7 days prior to planned study start.
  • Use of non-steroidal drugs within 30 days prior to start of the study
  • , uncontrolled cardiac, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug
  • Administration of any strong cytochrome P450 3A () inducers or inhibitors for 14 days prior to the first dose of study drug, and any P-glycoprotein inhibitors (for 2 days) or moderate inducers of CYP3A for 7 days
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    Phase 1a Dose Escalation

    Multiple dose levels of NX-2127 to be evaluated; determination of MTD/Phase 1b recommended dose

    Drug: NX-2127

  • Experimental
    Phase 1b Dose Optimization Stage 1 in CLL or SLL (Dose A)

    CLL/SLL patients whose disease has failed treatment with a BTK inhibitor

    Drug: NX-2127

  • Experimental
    Phase 1b Dose Optimization Stage 1 in MCL (Dose A)

    MCL patients whose disease has failed treatment with a BTK inhibitor and an anti-CD20 monoclonal antibody (mAb) based regimen

    Drug: NX-2127

  • Experimental
    Phase 1b Dose Optimization Stage 1 in FL, MZL or WM (Dose A)

    FL or MZL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTK inhibitor

    Drug: NX-2127

  • Experimental
    Phase 1b Dose Optimization Stage 1 in DLBCL (Dose A)

    DLBCL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen; or another/palliative regimen

    Drug: NX-2127

  • Experimental
    Phase 1b Dose Optimization Stage 1 in PCNSL (Dose A)

    PCNSL patients whose disease has failed at least 1 prior line of treatment

    Drug: NX-2127

  • Experimental
    Phase 1b Dose Optimization Stage 2 in CLL or SLL (Randomized to Dose A or Dose B)

    CLL/SLL patients whose disease has failed treatment with a BTK inhibitor

    Drug: NX-2127

  • Experimental
    Phase 1b Dose Optimization Stage 2 in MCL (Randomized to Dose A or Dose B)

    MCL patients whose disease has failed treatment with a BTK inhibitor and an anti-CD20 monoclonal antibody (mAb) based regimen

    Drug: NX-2127

  • Experimental
    Phase 1b Dose Optimization Stage 2 in FL, MZL or WM (Randomized to Dose A or Dose B)

    FL or MZL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTK inhibitor

    Drug: NX-2127

  • Experimental
    Phase 1b Dose Optimization Stage 2 in DLBCL (Randomized to Dose A or Dose B)

    DLBCL patients whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen; or another/palliative regimen

    Drug: NX-2127

  • Experimental
    Phase 1b Dose Optimization Stage 2 in PCNSL (Randomized to Dose A or Dose B)

    PCNSL patients whose disease has failed at least 1 prior line of treatment

    Drug: NX-2127

Interventions

  • DrugNX-2127

    Oral NX-2127

06

What researchers measure

Primary outcomes

  1. Number of Participants with Protocol Specified Dose-Limiting Toxicities

    Phase 1a

    Time frame: Up to 24 months

  2. To establish the MTD and/or recommended Phase 1b dosage(s) of NX-2127

    Phase 1a

    Time frame: Up to 24 months

  3. To evaluate the clinical activity of NX-2127 at the recommended Phase 1b dosage(s) based on overall response rate (ORR) as assessed by the Investigator

    Phase 1b

    Time frame: Up to 4 years

  4. Number of Participants with Adverse Events and Clinical Laboratory Abnormalities

    Phase 1a/1b

    Time frame: Up to 5 years

Secondary outcomes

  1. Pharmacokinetic (PK) Profile of NX-2127: Maximum Serum Concentration

    Phase 1a/1b - Sampling following the first dose, pre and post-dose at selected cycles, and at the end of treatment

    Time frame: Up to 5 years

  2. Duration of response (DOR) as assessed by the Investigator

    Phase 1a/1b

    Time frame: Up to 5 years

  3. Progression-free survival (PFS) as assessed by the Investigator

    Phase 1a/1b

    Time frame: Up to 5 years

  4. Overall survival (OS) as assessed by the Investigator

    Phase 1b

    Time frame: Up to 4 years

  5. To further evaluate the safety and tolerability of NX-2127 by collecting adverse events, treatment emergent adverse events, and incidence of all deaths

    Phase 1b

    Time frame: Up to 4 years

  6. Complete response (CR) rate / CR with incomplete marrow recovery as assessed by the Investigator

    Phase 1a/1b

    Time frame: Up to 5 years

07

Study locations

7 of 16 sites recruiting
08

References and documents

Publications

  • Zhang D, Harris HM, Chen J, Judy J, James G, Kelly A, McIntosh J, Tenn-McClellan A, Ambing E, Tan YS, Lu H, Gajewski S, Clifton MC, Yung S, Robbins DW, Pirooznia M, Skanland SS, Gaglione E, Mhibik M, Underbayev C, Ahn IE, Sun C, Herman SEM, Noviski M, Wiestner A. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts. Blood. 2023 Mar 30;141(13):1584-1596. doi: 10.1182/blood.2022016934. PubMed 36375120 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for May 2026, 60 months after the start.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's planned 60 months is close to that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2021
First posted
Apr 2, 2021
StartActual
May 5, 2021
Primary completionEst.
May 2026
CompletionEst.
May 2027
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04830137
Lead sponsor
Nurix Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 2, 2021
Start date
May 5, 2021
Primary completion
May 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Mar 20, 2026

Study contacts

Patient Outreach
Contact
nx2127001@nurixtx.com
(415)-230-7806 ext. 7806
Study Director
study director · Nurix Therapeutics, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion